|
Cellular Dynamics International (CDI) is a large scale manufacturer of human cells, created from induced pluripotent stem cells, for use in basic research, drug discovery and regenerative medicine applications. == History == Cellular Dynamics International (CD) was founded in 2004 by pluripotent stem cell biologist, James Thomson. He recognized that the way pluripotent stem cell technology could impact human health in the near future was to industrialize the process of manufacturing human cells in large quantities with high quality and consistency. CDI tendered an initial public offering in July 2013 under the ticker symbol ICEL. Human cells are considered to be a more predictive model and a replacement for other cellular models that serve as proxies, including animal cells, immortalized cell lines, and cadaveric cells. CDI offers several terminally differentiated cell types as catalog products: iCell® Cardiomyocytes, iCell Neurons, iCell Endothelial Cells, and iCell Hepatocytes. CDI’s MyCell® Products portfolio enables customer-provided donor samples to be reprogrammed, gene edited, and differentiated. The company also has several prototype products derived from pluripotent stem cells, including iCell Cardiac Progenitors, iCell Hematopoietic Progenitors, iCell Astrocytes, and iCell Skeletal Myoblasts. CDI has two locations. Their corporate headquarters are located in Madison, Wisconsin and a second facility resides at the Buck Institute for Aging in Novato, California. In 2013, CDI was awarded a contract from the California Institute for Regenerative Medicine to reprogram and bank iPS cells from 3,000 individuals.〔 , CDI has more than 800 patents and licensed technologies as part of their technology portfolio. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cellular Dynamics International」の詳細全文を読む スポンサード リンク
|